Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 28, Issue 5, Pages 899-905Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2018.01.067
Keywords
Zirconium-89; Tetrahydroxamate chelator; Monoclonal antibody; Molecular imaging; Positron emission tomography
Categories
Funding
- Canadian Institutes of Health Research [FDN-148465]
- Terry Fox Research Institute
Ask authors/readers for more resources
Two novel bifunctional tetrahydroxamate chelators 3 and 4 were synthesized and evaluated for labeling antibodies with Zr-89 for positron emission tomography imaging. Compared to previously reported tetrahydroxamate chelators 1 and 2 with an iminodiacetamide backbone, 3 and 4 were based on an extended iminodipropionamide and dipropylenetriamine backbone, respectively. Trastuzumab conjugates of 3 and 4 were efficiently labeled with Zr-89 (>95% radiochemical yield). The in vitro plasma stability of Zr-89-4-Trastuzumab and especially Zr-89-3-Trastuzumab was greatly improved over previously reported Zr-89-1-Trastuzumab and Zr-89-2-Trastuzumab, but their demetalation remained higher and faster than Zr-89-deferoxamine (DFO)-Trastuzumab. These observations were confirmed by PET imaging and biodistribution in mice, with significant higher bone uptake for Zr-89-4-Trastuzumab, followed by Zr-89-3-Trastuzumab, and to a lesser extent for Zr-89-DFO-Trastuzumab. Molecular modeling showed that 3 and 4 with an extended backbone could form eight-coordinate Zr-complexes as compared to only seven-coordinate Zr-complexes of 1 and 2. Our data suggest further elongation of linker length between hydroxamate motifs of this class of chelators is needed to reach a better Zr-coordination configuration and improve in vivo stability. (C) 2018 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available